Shares of Cel-Sci Corp (CVM) have dropped back to the mid-six dollar range, roughly two bucks lower than where shares traded just days earlier. As discussed previously, short interest in the stock had been gradually increasing as the share price about quadrupled since early 2019. I won't re-hash the entire Cel-Sci story here, please see my earlier blog posts for deeper insight. In short, tho, the company's lead product candidate, Multikine, is in the final stages of a global Phase III trial testing its effect in treating cancer of the head and neck. Multikine is different from traditional cancer treatments in that it is applied prior to the patient receiving Standard of Care (SoC) treatment, which is key because that is when the body's immune system is strongest; this is a key point, since Multikine harnesses the body's immune system to combat the cancer.
For investment purposes, the long side of the argument has it that Multikine is working since the trial is still ongoing past previous estimates of completion and since the IDMC recommended the trial continue after a review earlier this year. Read here for more on the subject. Two hundred and ninety eight total deaths is the magic number of 'events' that need to occur for the trial to end and according to the most recent company presentation dated this week, that has not yet occurred.
That could bode well for where CVM is headed...
Click the jump below for more.